title: Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease with Small Doses of Rituximab.
abstract: OBJECTIVE
  This study aims to observe the clinical efficacy of low-dose rituximab in patients with cryoglobulinaemia secondary to connective tissue diseases.
  
  
  METHODS
  Rituximab (100 mg) was infused in patients once a week for four weeks, combined with prednisone (20 mg) once a day, and reduced regularly. Treatment effect was observed regularly.
  
  
  RESULTS
  Joint pain, fever, rash and fatigue symptoms in patients eased. The serology (globulin, erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase and others) parameters returned to normal.
  
  
  CONCLUSIONS
  Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective, and can be used as a treatment option in this condition.
authors.affiliation: Department of Rheumatology, the Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Nephropathy, the Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Ning
authors.affiliation: Department of Rheumatology, the Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Rheumatology, the Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Rheumatology, the Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Rheumatology, the Second Hospital of Lanzhou University, Lanzhou 730030, China, e-mail: hailishencn@126.com.
authors.forename: H
authors.initials: H
authors.lastname: Shen
keywords: Connective tissue disease; cryoglobulinaemia; rituximab